跳转至内容
Merck
CN

S8139

舒林酸

≥98.0%

别名:

(Z)-5-氟-2-甲基-1-[4-(甲亚硫酰苯基)亚甲基]-1H-茚-3-醋酸

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C20H17FO3S
化学文摘社编号:
分子量:
356.41
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12161501
EC Number:
253-819-2
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

舒林酸, ≥98.0%

InChI key

MLKXDPUZXIRXEP-MFOYZWKCSA-N

InChI

1S/C20H17FO3S/c1-12-17(9-13-3-6-15(7-4-13)25(2)24)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9-

SMILES string

CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c3ccc(cc3)S(C)=O

biological source

synthetic (organic)

assay

≥98.0%

form

powder

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

solubility

methanol: 50 mg/mL

application(s)

forensics and toxicology
veterinary

originator

Merck & Co., Inc., Kenilworth, NJ, U.S.

Quality Level

Gene Information

正在寻找类似产品? 访问 产品对比指南

Application

处理人结肠癌细胞系可诱导 MRP1 和 MRP3,但不会诱导 MRP 家族的其他成员。据报道,可显着增加蒽环类药物(阿霉素、柔红霉素和表柔比星)以及替尼泊苷、VP-16 和长春新碱的细胞毒性。测试了舒林酸在体外对热诱导白蛋白变性的影响28,以及其与人血浆蛋白结合的能力。29

Biochem/physiol Actions

舒林酸是非甾体抗炎药,是具有抗增殖和凋亡作用的镇痛药。它抑制人结肠癌细胞中环氧合酶 2 的表达和活性25,26,并减轻腺瘤性息肉病患者的肿瘤负担。27
非甾体抗炎药;COX-1 的选择性抑制剂。

Features and Benefits

该化合物是由Merck & Co., Inc., Kenilworth, NJ, U.S.开发的。想要浏览其他由制药公司开发的化合物以及已批准药物/候选药物清单, 请单击此处
这种化合物是ADME毒性研究的特色产品。点击此处发现更多特色ADME毒性产品。在sigma.com/discover-bsm可了解更多关于生物活性小分子的其他研究领域。

pictograms

Skull and crossbonesHealth hazard

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Repr. 2 - Resp. Sens. 1 - Skin Sens. 1

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Stephen X Skapek et al.
Pediatric blood & cancer, 60(7), 1108-1112 (2013-01-03)
Desmoid fibromatosis (desmoid tumor, DT) is a soft tissue neoplasm prone to recurrence despite complete surgical resection. Numerous small retrospective reports suggest that non-cytotoxic chemotherapy using tamoxifen and sulindac may be effective for DT. We evaluated the safety and efficacy
Caihua Zhu et al.
Stem cells (Dayton, Ohio), 30(10), 2065-2075 (2012-06-02)
Pharmacological targeting of breast cancer stem cells (CSCs) is highly promising for the treatment of breast cancer, as the small population of CSCs appears responsible for tumor initiation and progression and also for resistance to conventional treatment. Here we report
D E Duggan
Drug metabolism reviews, 12(2), 325-337 (1981-01-01)
Sulindac is a prodrug which, following absorption, rapidly attains a metabolic equilibrium with its active pharmacophore, the sulfide metabolite. At the level of the whole body, the reversible interconversion sulindac in equilibrium sulfide, and the differing distributional and excretory properties
Nicole A Kratochwil et al.
Biochemical pharmacology, 64(9), 1355-1374 (2002-10-24)
In spite of the large amount of plasma protein binding data for drugs, it is not obvious and there is no clear consensus among different disciplines how to deal with this parameter in multidimensional lead optimization strategies. In this work
N M Davies et al.
Clinical pharmacokinetics, 32(6), 437-459 (1997-06-01)
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the indene acetic acid class. The absorption of sulindac is rapid when given orally. Sulindac is reversibly metabolised to sulindac sulphide which has anti-inflammatory and analgesic properties and is irreversibly metabolised to

商品

Protein-based drug transporters are expressed in Sf9 cells. Understanding the specific mechanisms of tumor cell transporters is an essential aspect of chemotherapeutic drug design.

Discover Bioactive Small Molecules for ADME/Tox

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持